var data={"title":"Cholestyramine resin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cholestyramine resin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5892?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cholestyramine-resin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cholestyramine resin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cholestyramine-resin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cholestyramine resin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150870\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Prevalite;</li>\n      <li>Questran;</li>\n      <li>Questran Light</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150871\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Novo-Cholamine;</li>\n      <li>Novo-Cholamine Light;</li>\n      <li>Olestyr;</li>\n      <li>PMS-Cholestyramine;</li>\n      <li>Questran;</li>\n      <li>Questran Light Sugar Free;</li>\n      <li>ZYM-Cholestyramine-Light;</li>\n      <li>ZYM-Cholestyramine-Regular</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150889\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antilipemic Agent, Bile Acid Sequestrant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150873\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Dosages are expressed in terms of anhydrous resin:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dyslipidemia:</b> Oral: Initial: 4 g 1 to 2 times/day; increase gradually over &ge;1-month intervals; maintenance: 8 to 16 g/day divided in 2 doses; maximum: 24 g/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic diarrhea due to bile acid malabsorption (off-label use): </b>Oral: Initial: 4 g once daily; increase by 4 g at weekly intervals in 1 to 4 divided doses; maximum: 36 g/day (Wilcox 2014). Additional data may be needed to further define the role of cholestyramine resin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperthyroidism (Graves&rsquo; disease) (adjunctive therapy) (off-label use): </b>Oral: 4 g twice daily (Tsai 2005) <b>or</b> 4 g 3 times daily (Mercado 1996). <b>Note:</b> Use in combination with an antithyroid drug (eg, methimazole or propylthiouracil) and propranolol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150884\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cholestyramine-resin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cholestyramine resin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dosages are expressed in terms of anhydrous resin:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dyslipidemia (off-label use):</b> Oral: 240 mg/kg/day in 2 to 3 divided doses; titrate dose to response and tolerance; maximum: 8 g/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150874\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150875\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution in renal impairment; may cause hyperchloremic acidosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389155\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary; not absorbed from the gastrointestinal tract.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150849\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prevalite: 4 g (1 ea, 42 ea, 60 ea) [contains aspartame; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Questran: 4 g (1 ea, 60 ea) [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g (1 ea, 60 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prevalite: 4 g/dose (231 g) [contains aspartame; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Questran: 4 g/dose (378 g) [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Questran Light: 4 g/dose (210 g) [sugar free; contains aspartame; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g/dose (210 g, 231 g, 239.4 g, 378 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150834\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49955381\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage Forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Packet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olestyr: 4 g (3 ea, 30 ea) [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olestyr Light: 4 g (3 ea, 30 ea) [sugar free; contains aspartame; orange and lemon-line flavors]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150853\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer prepared suspension orally. Not to be taken in dry form. Suspension should not be sipped or held in mouth for prolonged periods (may cause tooth discoloration or enamel decay). Administration at mealtime is recommended. Twice-daily dosing is recommended, but may be administered in 1 to 6 doses daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150852\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct in the management of primary hypercholesterolemia; pruritus associated with elevated levels of bile acids; regression of arteriolosclerosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722022\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chronic diarrhea due to bile acid malabsorption; Enhance elimination of digoxin when non-life-threatening toxicity occurs; Hyperthyroidism (Graves&rsquo; disease) (adjunctive therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150841\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Edema, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, dizziness, drowsiness, fatigue, headache, neuralgia, paresthesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Perianal skin irritation, skin irritation, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyperchloremic metabolic acidosis (children), increased libido, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, biliary colic, constipation, dental bleeding, dental caries, dental discoloration, diarrhea, diverticulitis, duodenal ulcer with hemorrhage, dysgeusia, dysphagia, eructation, flatulence, gallbladder calcification, gastric ulcer, gastrointestinal hemorrhage, hemorrhoidal bleeding, hiccups, intestinal obstruction (rare), melena, nausea, pancreatitis, rectal pain, steatorrhea, tongue irritation, tooth enamel damage (dental erosion), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Diuresis, dysuria, hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Adenopathy, anemia, bruise, hemorrhage, hypoprothrombinemia, prolonged prothrombin time, rectal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain, myalgia, osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Nocturnal amblyopia (rare), uveitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Asthma, dyspnea, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150856\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to bile acid sequestering resins or any component of the formulation; complete biliary obstruction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150838\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Chronic use may be associated with bleeding problems (especially in high doses); may be prevented with use of oral vitamin K therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: May produce or exacerbate constipation problems; initiate therapy at a reduced dose in patients with a history of constipation. Hemorrhoids may be worsened.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertriglyceridemia: Bile acid sequestrants should not be used in patients with baseline fasting triglyceride levels &ge;300 mg/dL or type III hyperlipoproteinemia since severe triglyceride elevations may occur. Use bile acid sequestrants with caution in patients with triglyceride levels 250 to 299 mg/dL and evaluate a fasting lipid panel in 4 to 6 weeks after initiation; discontinue use if triglycerides are &gt;400 mg/dL (Stone 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased absorption (orally administered drugs): Not to be taken simultaneously with many other medicines (decreased absorption).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients susceptible to fat-soluble vitamin deficiencies: Use with caution in patients susceptible to fat-soluble vitamin deficiencies. Absorption of fat soluble vitamins A, D, E, and K and folic acid may be decreased; patients should take vitamins &ge;4 hours before cholestyramine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299034\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150843\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9258&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: Cholestyramine Resin may decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Bile Acid Sequestrants may decrease the bioavailability of Amiodarone. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Bile Acid Sequestrants may decrease the absorption of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chenodiol: Bile Acid Sequestrants may decrease the serum concentration of Chenodiol.  Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce chenodiol adsorption in the gastrointestinal tract.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholic Acid: Bile Acid Sequestrants may decrease the absorption of Cholic Acid.  Management: Administer cholic acid at least 1 to 4 hours before or 4 to 6 hours after administration of any bile acid-binding products to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Oral): Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bile Acid Sequestrants may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Bile Acid Sequestrants may decrease the serum concentration of Estrogen Derivatives (Contraceptive).  Management: Administer estrogen-based oral contraceptives at least 1 to 4 hours prior to or 4 to 6 hours after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ezetimibe: Bile Acid Sequestrants may decrease the absorption of Ezetimibe.  Management: Administer ezetimibe at least 2 hours before or 4 hours after any bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: Bile Acid Sequestrants may decrease the absorption of Fibric Acid Derivatives.  Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluvastatin: Cholestyramine Resin may decrease the serum concentration of Fluvastatin.  Management: Administer fluvastatin at least 1 hour or greater (particularly with extended-release form) before, or at least 4 hours after cholestyramine to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: Bile Acid Sequestrants may decrease the absorption of Lomitapide.  Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Bile Acid Sequestrants may decrease the absorption of Loop Diuretics. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Bile Acid Sequestrants may decrease the absorption of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: Cholestyramine Resin may decrease the serum concentration of Methylfolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Fluoride (with ADE).  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron).  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Cholestyramine Resin may decrease the serum concentration of Mycophenolate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacin: Bile Acid Sequestrants may decrease the absorption of Niacin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: Bile Acid Sequestrants may decrease the serum concentration of Obeticholic Acid.  Management: Administer obeticholic acid at least 4 hours before or at least 4 hours after the administration of bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Cholestyramine Resin may decrease the serum concentration of PHENobarbital.  Management: Administer phenobarbital at least 1 hour before or 4-6 hours after administration of cholestyramine in order to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pravastatin: Bile Acid Sequestrants may decrease the serum concentration of Pravastatin.  Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Bile Acid Sequestrants may decrease the serum concentration of Progestins (Contraceptive).  Management: Administer oral progestin-containing contraceptives at least 1 to 4 hours prior to or 4 to 6 hours after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propranolol: Bile Acid Sequestrants may decrease the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raloxifene: Bile Acid Sequestrants may decrease the absorption of Raloxifene. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Cholestyramine Resin may decrease the serum concentration of Rosiglitazone.  Management: Administer rosiglitazone at least 2 hours prior to cholestyramine in order to minimize the likelihood of an interaction, and monitor patients closely for evidence of reduced rosiglitazone effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: Cholestyramine Resin may enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: Bile Acid Sequestrants may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Bile Acid Sequestrants may decrease the absorption of Tetracyclines. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Bile Acid Sequestrants may decrease the absorption of Thiazide and Thiazide-Like Diuretics. The diuretic response is likewise decreased. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ursodiol: Bile Acid Sequestrants may decrease the serum concentration of Ursodiol.  Management: Administer ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproic Acid and Derivatives: Cholestyramine Resin may decrease the serum concentration of Valproic Acid and Derivatives.  Management: Separate administration of valproic acid and cholestyramine by at least 3 hours whenever possible in order to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Bile Acid Sequestrants may diminish the therapeutic effect of Vancomycin.  Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs.  Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<b> Exceptions: </b>Calcipotriene; Calcitriol (Topical); Tacalcitol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Bile Acid Sequestrants may decrease the absorption of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150866\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Cholestyramine (especially high doses or long-term therapy) may decrease the absorption of folic acid, calcium, fat-soluble vitamins (vitamins A, D, E, and K), and iron. Management: Supplementation of folic acid, calcium, fat-soluble vitamins (vitamins A, D, E, and K), and iron may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150846\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150859\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipid concentrations increase during pregnancy as required for normal fetal development. When increases are greater than expected, supervised dietary intervention should be initiated. Bile acid sequestrants are recommended when treatment is needed (Avis 2009; Jacobson 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine is not absorbed systemically, but may interfere with maternal vitamin absorption; therefore, regular prenatal supplementation may not be adequate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389138\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Due to lack of systemic absorption, cholestyramine is not expected to be present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When treatment for hypercholesterolemia in breastfeeding women is needed, therapy with bile acid sequestrants may be considered (Jacobson 2015; NICE 2008). However, because use may interfere with maternal vitamin absorption, the manufacturer recommends caution be used if administered to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150860\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Supplementation of vitamins A, D, E, and K, folic acid, and iron may be required with high-dose, long-term therapy. Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389168\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Fasting lipid profile before initiating treatment, 3 months after initiation (within 4 to 6 weeks if baseline fasting triglycerides of 250 to 299 mg/dL), and every 6 to 12 months thereafter (Stone 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51237064\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Lipid treatment goals: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]):</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low risk (no risk factors):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C: &lt;160 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ApoB: No recommendation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate (&le;2 risk factors; 10-year risk &lt;10%) or high risk (diabetes; CKD stage 3 to 4; &ge;2 risk factors and 10-year risk 10% to 20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B: &lt;90 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Very high risk (ACS; carotid/peripheral artery disease; diabetes or CKD stage 3 to 4 with &ge;1 risk factors; HeFH; 10-year risk &gt;20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extreme risk (progressive atherosclerotic CVD after achieving LDL</i>\n      <i>&#8208;C &lt;70 mg/dL; CVD and diabetes, CKD stage 3 to 4, or HeFH; history of premature atherosclerotic CVD (&lt;55 years [males]; &lt;65 years [females]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C: &lt;55 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>National Lipid Association Dyslipidemia recommendations (NLA [Jacobson 2015]):</b> Adults &ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low-, moderate-, or high-risk patient categories: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B &lt;90 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: </b>For patients with diabetes plus 1 major ASCVD risk factor (ie, <i>high risk </i>category), treating to a non-HDL-C goal of &lt;100 mg/dL (LDL-C of &lt;70 mg/dL) may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Very high-risk patient category:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B &lt;80 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150837\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Forms a nonabsorbable complex with bile acids in the intestine, releasing chloride ions in the process; inhibits enterohepatic reuptake of intestinal bile salts and thereby increases the fecal loss of bile salt-bound low density lipoprotein cholesterol</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150855\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peak effect: 21 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (as insoluble complex with bile acids)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150858\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Cholestyramine Light Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (60): $201.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Cholestyramine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (60): $202.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Prevalite Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (42): $214.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Questran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (1): $7.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Cholestyramine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/dose (378 g): $131.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Prevalite Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/dose (231 g): $137.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Questran Light Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/dose (210 g): $187.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Questran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/dose (378 g): $186.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150861\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Choles (TW);</li>\n      <li>Colestiramina (CL, CO, PY);</li>\n      <li>Colestrol (IT);</li>\n      <li>Efensol (ES);</li>\n      <li>Kolestran (TR);</li>\n      <li>Lipocol-Merz (DE);</li>\n      <li>Lipramina (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Olipo (BD);</li>\n      <li>Quantalan (CH, PT);</li>\n      <li>Quantalan Zuckerfrei (AT);</li>\n      <li>Questran (AE, BB, BE, BG, DK, EC, EG, FI, FR, GB, GR, HK, HN, IE, IS, IT, KR, KW, LU, MX, NL, NO, NZ, QA, SA, SE, SI, TH, VN);</li>\n      <li>Questran Light (AR, BB, BR, CZ, MY);</li>\n      <li>Questran Lite (AU, NZ, PH, ZA);</li>\n      <li>Questran Loc (DK, SE);</li>\n      <li>Resincolestiramina (ES, SG, TH, UY);</li>\n      <li>Semide (TW);</li>\n      <li>Sequest (ID);</li>\n      <li>Vasosan (PL);</li>\n      <li>Vasosan P-Granulat (DE);</li>\n      <li>Vasosan S-Granulat (DE, FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26207323\"></a>Alswat KA. Role of cholestyramine in refractory hyperthyroidism: a case report and literature review. <i>Am J Case Rep</i>. 2015;16:486-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/26207323/pubmed\" target=\"_blank\" id=\"26207323\">26207323</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10348831\"></a>American Gastroenterological Association (AGA). American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. <i>Gastroenterology</i>. 1999;116(6):1461-1463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/10348831/pubmed\" target=\"_blank\" id=\"10348831\">10348831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? <i>Curr Opin Lipidol.</i> 2009;20(6):484-490. doi: 10.1097/MOL.0b013e3283319127. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/19741526/pubmed\" target=\"_blank\" id=\"19741526\">19741526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22075299\"></a>Borghede MK, Schl&uuml;tter JM, Agnholt JS, Christensen LA, Gormsen LC, Dahlerup JF. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea. <i>Eur J Intern Med</i>. 2011;22(6):e137-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/22075299/pubmed\" target=\"_blank\" id=\"22075299\">22075299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3341874\"></a>Henderson RP and Solomon CP, &ldquo;Use of Cholestyramine in the Treatment of Digoxin Intoxication,&rdquo; <i>Arch Intern Med</i>, 1988,148(3):745-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/3341874/pubmed\" target=\"_blank\" id=\"3341874\">3341874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"4894463\"></a>Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea associated with ileal resection. <i>N Engl J Med</i>. 1969;281(8):397-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/4894463/pubmed\" target=\"_blank\" id=\"4894463\">4894463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. <i>J Clin Lipidol.</i> 2015;9(6 Suppl):S1-122.e1. doi: 10.1016/j.jacl.2015.09.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/26699442/pubmed\" target=\"_blank\" id=\"26699442\">26699442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/28437620/pubmed\" target=\"_blank\" id=\"28437620\">28437620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16971976\"></a>McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo; [published correction appears in <i>Can J Cardiol</i>. 2006, 22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/16971976/pubmed\" target=\"_blank\" id=\"16971976\">16971976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8784067\"></a>Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, Espinoza-de los Monteros AL. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. <i>J Clin Endocrinol Metab</i>. 1996;81(9):3191-3193.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/8784067/pubmed\" target=\"_blank\" id=\"8784067\">8784067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      National Institute for Health and Care Excellence (2008) Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: NICE. (Clinical Guideline 71). Available at: http://www.nice.org.uk/CG71.8784067</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olestyr (cholestyramine) [product monograph]. Montr&eacute;al, Quebec, Canada: Pharmascience; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prevalite (cholestyramine) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Questran Powder, Questran Light [prescribing information]. Spring Valley, NY: Par Pharmaceuticals; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].<i>Circulation</i>. 2013; doi: 10.1161/01.cir.0000437738.63853.7a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15853819\"></a>Tsai WC, Pei D, Wang TF, et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. <i>Clin Endocrinol (Oxf)</i>. 2005;62(5):521-524.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/15853819/pubmed\" target=\"_blank\" id=\"15853819\">15853819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21180614\"></a>Walters JR, Pattni SS. Managing bile acid diarrhoea. <i>Therap Adv Gastroenterol</i>. 2010;3(6):349-357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/21180614/pubmed\" target=\"_blank\" id=\"21180614\">21180614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17298762\"></a>Westergaard H, &ldquo;Bile Acid Malabsorption,&rdquo; <i>Curr Treat Options Gastroenterol</i>, 2007, 10(1):28-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/17298762/pubmed\" target=\"_blank\" id=\"17298762\">17298762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24602022\"></a>Wilcox C, Turner J, Green J. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. <i>Aliment Pharmacol Ther</i>. 2014;39(9):923-939.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-drug-information/abstract-text/24602022/pubmed\" target=\"_blank\" id=\"24602022\">24602022</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9258 Version 158.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F150870\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F150871\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F150889\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F150873\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F150884\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F150874\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F150875\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13389155\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F150849\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F150834\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49955381\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F150853\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F150852\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722022\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F150841\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F150856\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F150838\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299034\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F150843\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F150866\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F150846\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F150859\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13389138\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F150860\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13389168\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F51237064\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F150837\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F150855\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F150858\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F150861\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9258|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cholestyramine-resin-patient-drug-information\" class=\"drug drug_patient\">Cholestyramine resin: Patient drug information</a></li><li><a href=\"topic.htm?path=cholestyramine-resin-pediatric-drug-information\" class=\"drug drug_pediatric\">Cholestyramine resin: Pediatric drug information</a></li></ul></div></div>","javascript":null}